Agreement expands Mycovia’s commercialization that is global for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia continues to rapidly develop VT-1161 as a possible first FDA-approved remedy for recurrent vulvovaginal candidiasis
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a special permit and development and technology transfer contract with Gedeon Richter Plc., located in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, an dental product that is antifungal, is in stage 3 medical studies when it comes to remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million females global every year.
“We are excited to partner with Gedeon Richter, an organization with strong market leadership in women’s health, to build up and commercialize VT-1161, our possible first FDA-approved treatment plan for RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. “VT-1161 is well placed to deal with the requirements of the scores of women that have problems with vexation, discomfort and psychological stress due to RVVC and they are looking for a treatment option that is new. We look ahead to formalizing our commercial strategy and launch plans even as we rapidly advance VT-1161 through the hospital and prepare our submission that is regulatory. Continuar leyendo «Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand»